Lung Cancer News
While eribulin is not superior in prolonging OS compared with the established second- and third-line therapies, it may have a role as a third-line agent.
Proton Beam Therapy Plus Chemotherapy May Provide Benefit in Unresectable Non-small Cell Lung Cancer
Researchers enrolled 64 patients with unresectable NSCLC to receive concurrent passively scattered PBT and weekly infusions of carboplatin-paclitaxel.
Among patients with relapsed malignant mesothelioma, tremelimumab does not improve OS compared with placebo.
With concurrent chemotherapy, proton-beam therapy is safe and may be effective for patients with limited-stage small-cell lung cancer.
The FDA granted orphan drug designation today to TPX-0005 — a small molecule kinase inhibitor — for the treatment of NSCLC with ALK, ROS1, or NTRK rearrangements.
The US Food and Drug Administration approved the combination of dabrafenib and trametinib for metastatic non-small cell lung cancer (NSCLC) with a BRAFV600E mutation.
Study results suggest that first-line treatment of advanced NSCLC with nivolumab does not prolong PFS or OS compared with chemotherapy, though nivolumab had a better safety profile.
Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.
The 12-month overall survival milestone rate correlates with OS hazard ratio in trials of metastatic non-small cell lung cancer and could be a valuable secondary endpoint.
Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.
The addition of palifosfamide to carboplatin and etoposide failed to prolong survival among patients with extensive-stage small-cell lung cancer.
Nivolumab alone or combined with ipilimumab provided durable responses in patients with advanced small-cell lung cancer whose disease progressed on prior platinum therapies.
Veliparib added to cisplatin and etoposide improves progression-free survival among patients with extensive stage small-cell lung cancer.
Vemurafenib improves outcomes among patients with non-small cell lung cancer with a BRAFV600 mutation.
Adaptive escalation of radiation therapy based on midtreatment residual tumor FDG-PET may improve local control among patients with locally advanced non-small cell lung cancer.
Squamous cell lung cancers, a form of NSCLC, are glucose-dependent, while adenocarcinoma NSCLC tumors are largely glucose-independent.
Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.
Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.
The prognostic marker, which was evaluated among patients with stage III NSCLC, held after adjusting for variables including chemoradiation approach and performance status.
A liquid biopsy analysis shows inter- and intra-patient heterogeneity of EGFR resistance mutations among patients with lung adenocarcinoma who received EGFR-directed TKI therapy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Low-fat Diet and Breast Cancer
- The Adverse Effects of Sarcoma Treatment in Cancer Survivors
- Some Patients With Terminal Cancer Receive Unnecessary Aggressive Treatment
- Anti-CD19 CAR-T Cells May Be Safe and Effective in Chronic Lymphocytic Leukemia
- Active Surveillance and Watchful Waiting for Low-risk Prostate Cancer
- Weight in Adolescence May Predict Colorectal Cancer Risk
- Haploidentical Transplantation Effective as Front-line Therapy for Standard-risk ALL
- Ipilimumab Indication Expanded To Include Pediatric Unresectable or Metastatic Melanoma
- Immune-mediated Hepatitis: Challenges in Management
- Phase 1 Study of A Dendritic Cell Vaccine for High-grade Glioma and Glioblastoma